Sharemaestro Newsreel

Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA

Assenagon Asset Management S.A. significantly increased its stake in Teva Pharmaceutical Industries Ltd. by 128.1% in the second quarter, now holding over 3 million shares valued at approximately $103.5 million. Institutional investors collectively own 54.05% of Teva, and analysts maintain a "Moderate Buy" rating …

Dimensional Fund Advisors LP Raises Position in Bausch Health Cos Inc. $BHC

Dimensional Fund Advisors LP significantly increased its stake in Bausch Health Cos Inc. by 10.8% in the first quarter of 2026, acquiring 350,823 additional shares to reach a total of 3.6 million shares. Other institutional investors also raised their positions, with institutions now owning …

ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIP) 2026-08-08

ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Canopy Growth posts 13% revenue rise and narrows losses in Q1 fiscal 2027, shares up 5%.

Canopy Growth Corporation reported a 13% increase in net revenue to C$81.2 million for the first quarter of fiscal 2027, exceeding analyst estimates. The company significantly narrowed its adjusted EBITDA losses by 59% to C$3.2 million and reduced its net loss by 68% year-over-year. …

Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV

Assenagon Asset Management S.A. has acquired 1,540,928 shares of Indivior PLC (NASDAQ:INDV), representing a 1.26% stake worth approximately $63.2 million. Institutional investors now collectively own 60.33% of the company. Indivior recently reported strong quarterly earnings of $5.75 per share, surpassing full-year analyst expectations, while …

Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Elanco Animal Health (NYSE:ELAN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $29.09, significantly above its current share price of $22.06. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $0.34 on revenues of …

Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi

Canopy Growth Q1 Earnings Call Highlights

Canopy Growth (NASDAQ: CGC) reported a 13% increase in Q1 fiscal 2027 net revenue to C$81.2 million, driven by growth in its cannabis and Storz & Bickel businesses. The company narrowed its adjusted EBITDA loss by 59% to C$3.2 million and aims for positive …

Caring Brands Inc (CABR) Stock News Today

This page provides stock news for Caring Brands Inc (CABR), showing its current stock price, market cap, and a note that more news is coming soon. As of the last close, CABR was trading at $1.440, up 7.87%, with a market capitalization of $12.14 …

BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had approximately 411 employees worldwide as of March 2026, representing a 3.8% decline since 2023. The company is actively hiring, though job postings have decreased significantly, and its workforce is primarily concentrated in the United States. Employee sentiment is …

Emergent BioSolutions Inc (EBS) Stock News Today

This article provides the latest stock news for Emergent BioSolutions Inc (EBS), including its recent earnings report. The company experienced MCM growth but also reported NARCAN impairment in its Q2 2026 earnings. The stock closed at $4.840, down 9.23%.

OrganiGram Holdings Inc (OGI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for OrganiGram Holdings Inc (OGI), detailing future EPS and revenue growth estimates. It highlights that the expected revenue for the next quarter is $70.48 million and anticipates an EPS of USD -0.00 for the upcoming quarter, contrasting with …

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-08-07

This article announces that Neurocrine Biosciences, Inc. (NBIX) has published its slide deck in conjunction with its Q2 2026 earnings call. The earnings call presentation was made on August 7, 2026. The article was written by the Seeking Alpha Transcripts team, which regularly publishes …

Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC

PKO BP BANKOWY Universal Pension Society JSC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 23.1% in the second quarter, now holding 170,802 shares valued at $28.8 million. This move highlights continued institutional investor interest, with several other hedge funds also boosting their …

ETFs Investing in Neurocrine Biosciences, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Neurocrine Biosciences, Inc. The list, sorted by market value, provides details such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV …

How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors

Neurocrine Biosciences recently reported strong Q2 2026 results, with significant revenue and net income, alongside a new equity shelf registration tied to an ESOP offering. This dual development highlights the company's efforts to strengthen employee ownership and financial flexibility. The article discusses how these …

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen

ANI Pharmaceuticals (NASDAQ:ANIP) recently had its stock rating lowered from "strong buy" to "buy" by Wall Street Zen, though the broader analyst consensus remains a "Moderate Buy" with an average target price of $106.83. This downgrade follows strong second-quarter results where the company exceeded …

Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Amphastar Pharmaceuticals (NASDAQ:AMPH) received an upgrade from Wall Street Zen to a "strong-buy" rating, despite a more cautious "reduce" consensus rating from other analysts. The company's recent quarterly results surpassed expectations with revenues of $183.9 million and adjusted EPS of $0.91, outperforming estimates. Institutional …

Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen

Wall Street Zen has upgraded Evolus (NASDAQ:EOLS) from a "hold" to a "buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $14.50. Shares of Evolus opened at $7.59, a 2.4% increase, and are nearing their 12-month high. …

Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen has upgraded Pacira BioSciences (NASDAQ:PCRX) to a "strong-buy" rating from "buy," despite the broader analyst consensus remaining "Hold" with an average price target of $29.80. The company reported strong quarterly earnings, beating analyst estimates with EPS of $0.73 and revenue of …

Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Wall Street Zen

Wall Street Zen has downgraded Collegium Pharmaceutical (NASDAQ:COLL) from "Buy" to "Hold," leading to mixed analyst views but a consensus "Moderate Buy" rating with an average price target of $52.60. Despite exceeding Q2 earnings expectations with strong ADHD portfolio growth, the company lowered its …

Elanco Animal Health Q2 Earnings Call Highlights

Key Points Interested in Elanco Animal Health Incorporated? Here are five stocks we like better. Strong Q2 performance: Elanco reported revenue of $1.368 billion, up 10% year over year, while adjusted EBITDA rose 21% to $288 million and adjusted EPS increased 31% to $0.34. …

Canopy Growth (NASDAQ:CGC) Stock Rating Upgraded by Wall Street Zen

The Bull Case For Trulieve Cannabis (TRLV) Could Change Following Surging Losses On Slightly Lower Sales

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX) has been upgraded to a "strong-buy" rating by Wall Street Zen. The company reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, with revenue increasing 33.6% year over year. Despite a recent price target decrease from Royal Bank …

Alkermes (ALKS) Faces A Fresh Valuation Test Following Earnings Guidance And Shelf Filing

elanco animal health inc. Positive Earnings Pre-Announcements

Elanco Animal Health Inc. (ELAN) has pre-announced positive earnings for FY26, with an updated estimated range of $5.090-$5.140 Billion, up from $5.010-$5.085 Billion. This follows a recent boost in their FY26 outlook and a 7% stock increase reported on August 5, 2026. The company …

Lantheus (LNTH) Stock Shrugs Off Solid Profit As Margin Questions Linger

Lantheus Holdings (LNTH) stock saw a minimal price change despite solid Q2 earnings, with revenue meeting expectations and EPS remaining flat year-over-year. Investors are weighing the company's strong trailing P/E against questions about future growth pillars like Alzheimer’s diagnostics and operating leverage, especially after …

Collegium Pharmaceutical (NASDAQ:COLL) Releases Earnings Results, Beats Estimates By $0.20 EPS

Collegium Pharmaceutical (NASDAQ:COLL) announced quarterly earnings that surpassed analyst estimates, reporting $1.92 EPS against a consensus of $1.72, and revenue of $199.88 million. The company experienced strong growth in its ADHD portfolio, particularly with JORNAY PM and the recent AZSTARYS acquisition, but faced declines …

Emergent Biosolutions Q2 Earnings Call Highlights

Key Points Interested in Emergent Biosolutions Inc.? Here are five stocks we like better. Q2 performance exceeded expectations: Revenue reached $234 million and adjusted EBITDA rose to $97 million, driven by accelerated medical countermeasure deliveries and strong U.S. government contract activity. NARCAN competition is …

Curious about Kamada (KMDA) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Kamada (KMDA) is expected to report Q2 earnings of $0.12 per share, a 7.7% decline year-over-year, with revenues forecasted at $51.62 million, an increase of 15.4%. Analysts predict "Revenues-Distribution" at $10.55 million (+67% change) and "Revenues-Proprietary products" at $41.07 million (+6.9% change). The stock …

Viatris (VTRS) Stock Looks Stuck Between Higher Guidance And Wider Losses

Zhengye Biotechnology Holding Ltd (ZYBT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Zhengye Biotechnology Holding Ltd (ZYBT), focusing on future EPS and revenue growth estimates. As of August 8, 2026, ZYBT's stock closed at $1.890 USD, down 9.57%, with a market cap of $89.57 million. The page includes an …

Canopy Growth (NASDAQ:CGC) Announces Quarterly Earnings Results

Canopy Growth (NASDAQ:CGC) reported stronger-than-expected quarterly earnings, with revenue up 13% year-over-year to C$81.2 million and a narrowed loss of C$0.02 per share, surpassing analyst estimates. The company showed improved adjusted gross margins and a reduced adjusted EBITDA loss, targeting positive adjusted EBITDA in …

Amphastar Pharmaceuticals, Inc. SEC Filing (Aug 7, 2026)

This article reports on Amphastar Pharmaceuticals, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of securities, detailing the class of securities, the broker involved (UBS Financial Services, Inc.), the number of shares, aggregate market value, and the …

Healthcare giant slashes key consultation fee to beat rivals

CVS Health (CVS) is targeting the earliest point in a customer's weight-loss drug decision: the first consultation. On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee. That is the …